The FDA issued draft guidance laying out how sponsors should develop and submit biologics license applications for individualized human genome editing products, alongside postapproval management considerations. The proposal introduces an “Individualized Feature Space” concept—predefined boundaries for allowable variation in genome-editing components (such as gRNA spacers) so patient-specific therapies can remain within a single BLA scope. Acting FDA Commissioner Kyle Diamantas said the guidance addresses why individualized rare-disease treatment can’t rely on one-size-fits-all regulatory approaches. Sponsors can use the framework to pursue approvals without always repeating clinical trials for each permissible variation, as long as the changes fall within the specified limits. The draft (FDA-2026-D-11783) is open for public comment through November 27. Jefferies analyst Maury Raycroft called the move “de-risking data & reg catalysts,” pointing to the guidance as a constructive signal for the gene editing sector after a difficult stretch in the past year.